Source: International Congress 2018 – Cardiovascular morbidities in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Fesenko (Dnipro, Ukraine), K. Bogatska (Dnipro, Ukraine). Safety of nebivolol and bisoprolol in patients (pts) with COPD and stable angina.. 738

Member's Comments

No comment yet.

Related content which might interest you: Effects of nebivolol and ivabradine on the left ventricular diastolic function in patients (pts) with COPD and stable angina Source: International Congress 2014 – COPD markers Year: 2014 Effects of bisoprolol and nebivolol on the left ventricular diastolic function in patients (pts) with COPD and stable angina. Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD Year: 2020 Effects of nebivolol and ivabradine on myocardial ischemia in patients (pts) with COPD and stable angina during 24-hour ambulatory Holter ECG monitoring. Source: International Congress 2017 – Extrapulmonary comorbidities in COPD Year: 2017 Effects of tiotropium bromide and fluticasone propionate/salmeterol on myocardial ischemia in patients (pts) with COPD and stable angina during 24-hour ambulatory Holter ECG monitoring Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Efficacy and safety of salmeterol in patients with bronchial asthma (BA) and ischemic heart disease (IHD) Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002 Efficacy and safety of b 2 –agonists and ipratropium bromid in patients with bronchial asthma(BA) and ischemic heart disease (IHD) Source: Eur Respir J 2003; 22: Suppl. 45, 420s Year: 2003 Use of bisoprolol: comparison of symptoms worsening in patients with asthma and COPD Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Safety of tiotropium in patients with cardiac events in the TIOSPIR™ trial Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Once-daily QVA149 has a good safety profile in patients with COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease: A nationwide population-based study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Effect of olodaterol once-daily on heart rate in GOLD 2–4 COPD patients Source: International Congress 2017 – COPD management Year: 2017 Safety of long-term sildenafil 20 or 80 mg TID in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Myocardial ischemia in patients (pts) with COPD and stable angina during 24-hour ambulatory Holter ECG monitoring Source: International Congress 2015 – COPD: interesting notes Year: 2015 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Onset of action of aclidinium (ACL), glycopyrronium (GLY) and tiotropium (TIO): A comparison in COPD patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015